The OCMX™ is pleased to announce the listing of AmpliPharm to its online portal which offers financial networks the ability to learn more about this exciting opportunity.

SUWANEE, GA, June 09, 2023 /24-7PressRelease/ — AmpliPharm gets listed on THE OCMX™

AmpliPharm is a newly formed specialty pharmaceutical development company focusing on specialty markets in which company management has significant operational and commercial experience. AmpliPharm develops pharmaceuticals for unmet medical need of complex dosed oral oncology medications.

The OCMX™ is pleased to announce the listing of AmpliPharm to its online portal which offers financial networks the ability to learn more about this exciting opportunity.

The OCMX™ has spent considerable time completing its due diligence on AmpliPharm and concluded that there is indeed a tremendous potential for this company.

The OCMX™ noted that AmpliPharm exhibits the main components of any solid opportunity, namely a solid management team, a great track record, and several key competitive advantages.

AmpliPharm targets unmet medical needs of complex dosed medications with high pill burden, dose accuracy, multiple patient copays, and frequent dose adjustments have long been problems for oncology patients and their oncologists.
AmpliPharm patented technology will eliminate pill burden, allow physicians to more accurately dose medications and greatly reduce the number of patient copays.

AmpliPharm will file it’s lead product with the FDA after completion of a BIO equivalence.
Future pharmaceutical development with focus on the pediatric oncology medications and combination therapy for a new indication in Pediatric Glioblastoma.

• AmpliPharm’s lead product will eliminate the complex dosing of multiple capsules and bottles which have led to medication errors with some errors leading to death.
• AmpliPharm’s lead product will decrease the number of patient copays up to $90 per month for some patients.
• The lead product will be the only product to give prescribing physicians the ability to accurately dose the medication per patient without the rounding off a dose.
• Lower risk pharmaceutical opportunity with AmpliPharm completion of the Chemistry Manufacturing and Controls, drug stability, human factor studies and permeability studies.
• Patented technology gives FDA Orange Book listing for protection against competitors.
• Favorable insurance coverage and reimbursement with pricing protection

Gary Payton, R. Ph. – Founder & President
• Over 23 years of pharmaceutical industry experience with Schering-Plough, Oscient Pharmaceuticals, Genta, Biogen.
• Extensive experience in managed markets in the U.S. and Puerto Rico focusing on oncology, hepatitis, and respiratory products.
• Founding member of Ascio Pharmaceuticals.

Dr. Keith Watts, DBA – Financial Officer
• Over 28 years of pharmaceutical industry experience with AstraZeneca and Schering.
• Participated in the launch of 14 new products with sales as high as $1 billion.
• Adjunct Faculty specializing in healthcare administration, healthcare economics.

• AmpliPharm lead product is the Standard of Care for Glioblastoma in an improved dosage form.
• Glioblastoma the most common malignant brain and CNS tumor (14.6% of all tumors and 77%-81% of all primary malignant CNS tumors).
• 98% Gross Margin of AMPLIPHARM lead product.
• Annual units per year projected at 250,000.
• Growth rate projected at 10% after launch to 20%.

• Stability studies completed with results in FDA specifications.
• Pharmaceutical Dissolution studies completed with results in FDA specifications.
• Three Human Factor Studies completed with results in FDA specifications.
• Issued patents on drug formulation.
• Issued patents on drug dose delivery medical device.

The OCMX™, established in 2009, is a next generation investor relations and marketing outreach firm. Through our online OCMX portal, we connect companies with financial networks, generating interest and awareness for their opportunity.

Contact Us
TD Canada Trust Tower
161 Bay Street, 45th Floor
Toronto, Ontario, M5J 2S1
Tel: 1-866-209-6862
Email: [email protected]

For the original version of this press release, please visit here